Abstract:Establishing new surrogate end points for monitoring response to treatment is needed for current therapy modalities and for new therapeutic strategies including molecular targeted cancer therapies. PET as a functional imaging technology provides rapid, reproducible, noninvasive in vivo assessment and quantification of several biologic processes targeted by these therapies. PET is useful in a variety of clinical relevant applications, including distinguishing between radiation necrosis and tumor recurrence, determining the resectability of recurrent tumor, and evaluating response to therapy. FDG-PET has demonstrated efficacy for monitoring therapeutic response in a wide range of cancers, including breast, esophageal, lung, head and neck, and lymphoma. FDG-PET can assess tumor glucose use with high reproducibility. Following therapy, the decrease of glucose use correlates with the reduction of viable tumor cells. FDG-PET allows the prediction of therapy response early in the course of therapy and determining the viability of residual masses after completion of treatment. The molecular basis for the success of FDG-PET is the rapid reduction of tumor glucose metabolism in effective therapies. Of even higher clinical relevance is the accurate identification of nonresponders in patients without a significant change in tumor glucose metabolism after initiation of therapy. PET imaging can easily visualize these changes in metabolic activity and indicate, sometimes within hours of the first treatment, whether or not a patient will respond to a particular therapy. In contrast to CT, MR imaging, or ultrasound, PET imaging allows identification of responding and nonresponding tumors early in the course of therapy. With this information, physicians can rapidly modify ineffective therapies for individual patients and thereby potentially improve patient outcomes and reduce cost. One of the major limitations for the routine application of FDG-PET imaging for therapy monitoring is that no generally accepted cutoff values have been established to differentiate optimally between responders and nonresponders. The patient series are still relatively small and frequently consist of different tumor types and different therapy regimens. Prospective studies including a sufficient number of patients are needed to define cutoff values to differentiate between responder and nonresponder for different tumors and different treatment regimes. In the future, PET imaging can also serve in the evaluation of new therapeutic agents, new experimental treatments, and specifically in monitoring clinical phase II studies.

A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology

Predicting Response to Radiotherapy in Tumors with PET/CT: when and How?

A systematic review of PET and PET/CT in oncology: A way to personalize cancer treatment in a cost-effective manner?

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations

Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18F-FDG-PET-CT and/or diffusion-weighted MRI

MRI and 18F-FET PET for Multimodal Treatment Monitoring in Patients with Brain Metastases: A Cost-Effectiveness Analysis

Computerized PET/CT Image Analysis in the Evaluation of Tumour Response to Therapy.

Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews

Positron Emission Tomography/computerized Tomography for Tumor Response Assessment-a Review of Clinical Practices and Radiomics Studies.

Monitoring response to treatment in patients utilizing PET

Advanced Imaging to Predict Response to Chemotherapy in Colorectal Liver Metastases – a Systematic Review

A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models

Evaluation of the efficiency of peptide receptor radionuclide therapy in patients with metastatic prostate carcinoma: A protocol for systematic review and meta-analysis

Evaluating an analytical prediction algorithm of positron emitter distributions in patient data for PET monitoring of carbon ion therapy: A simulation study

Predictive Models for Assessing Patients' Response to Treatment in Metastatic Prostate Cancer: A Systematic Review

Update on the Use of PET/MRI Contrast Agents and Tracers in Brain Oncology: A Systematic Review

Oncology Sequence Models In Health Technology Assessment-A Literature Review

Health Economic Evaluation of Proton Therapy for Lung Cancer: A Systematic Review

Heterogeneity of absorbed dose distribution in kidney tissues and dose–response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review

Analysis methods for in-beam PET images in proton therapy treatment verification: a comparison based on Monte Carlo simulations

A Systematic Review of PET Textural Analysis and Radiomics in Cancer